US2010203511A1PendingUtilityA1

Retinoid metabolizing protein

Assignee: UNIV KINGSTONPriority: Jun 21, 1996Filed: Dec 18, 2008Published: Aug 12, 2010
Est. expiryJun 21, 2016(expired)· nominal 20-yr term from priority
C07K 2319/00A61K 38/00Y10S435/975C12N 9/0077
66
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Amino acid sequences and corresponding nucleic acid sequence of retinoid metabolizing protein found in human, mouse and zebrafish are described, as well as methods of using same.

Claims

exact text as granted — not AI-modified
1 . A method of screening drugs for their effect on expression of a gene wherein the gene is inducible by a retinoid, comprising:
 (A) exposing a recombinant DNA to a said drug, and   (B) determining the effect on gene expression,   wherein the recombinant DNA comprises:   (i) a nucleotide sequence selected from the group consisting of:
 (a) SEQ ID NO:33; 
 (b) SEQ ID NO:34; 
 (c) SEQ ID NO:35; and 
 (d) a fragment of (a), (b) or (c), wherein said DNA fragment possesses promoter activity; and 
   (ii) at least one structural gene.   
     
     
         2 . The method of  claim 1  including exposing the recombinant DNA in the presence of a said retinoid. 
     
     
         3 . The method of  claim 1  wherein the at least one structural gene comprises a reporter gene that does not metabolize retinoic acid. 
     
     
         4 . The method of  claim 1  wherein the at least one structural gene comprises at least one cytochrome P450. 
     
     
         5 . The method of  claim 1  wherein determining the effect on gene expression includes ascertaining the effect on transcription of the gene. 
     
     
         6 . The method of  claim 2  wherein the retinoid is a retinoic acid. 
     
     
         7 . The method of  claim 6  wherein the retinoic acid is all-trans-retinoic acid. 
     
     
         8 . The method of  claim 1  wherein said recombinant DNA includes the sequence TGAACTNNNNNTGAACT, where “N” can be any nucleotide and there can be 0 to 5 N (SEQ ID NO:39). 
     
     
         9 . The method of  claim 8  wherein there are 5 N. 
     
     
         10 . The method of  claim 8  wherein said recombinant DNA further includes the sequence TCTGASSAAGKTAAC (SEQ ID NO:40) downstream from the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39). 
     
     
         11 . The method of  claim 10  wherein said recombinant DNA further includes the sequence AATT between the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and the sequence TCTGASSAAGKTAAC (SEQ ID NO:40). 
     
     
         12 . The method of  claim 10  wherein there are up to six nucleotides between the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and the sequence TCTGASSAAGKTAAC (SEQ ID NO:40). 
     
     
         13 . The method of  claim 8  wherein said recombinant DNA further includes the sequence CAATTAAAGA (SEQ ID NO:41) upstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39). 
     
     
         14 . The method of  claim 1  wherein said recombinant DNA includes the sequence CAATTAAAGATGAACTTTGGGTGAACTAATT (SEQ ID NO:42). 
     
     
         15 . The method of any of  claims 1  to  14  wherein said recombinant DNA includes the sequence TATAA. 
     
     
         16 . The method of  claim 8 ,  9  or  13  wherein said recombinant DNA includes the sequence TATAA downstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39). 
     
     
         17 . The method of  claim 10  or  11  wherein said recombinant DNA includes the sequence TATAA downstream of the sequence TCTGASSAAGKTAAC (SEQ ID NO:40). 
     
     
         18 . The method of  claim 8  wherein said recombinant DNA includes the sequence TATAA located downstream of the sequence TGAACTNNNNNTGAACT (SEQ ID NO:39) and spaced up to about 55 nucleotides therefrom.

Join the waitlist — get patent alerts

Track US2010203511A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.